AVBP
ArriVent BioPharma, Inc.
16.70$
-1.1%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| – | +324.8% | -10.8% | +68.6% | +21.2% | |
| – | +325.2% | -12.4% | +41.9% | +46.7% | |
| – | +338.2% | -7.9% | -50.6% | -38.7% | |
| – | +338.2% | -7.9% | +45.5% | +42.9% | |
| – | +100.0% | +52.2% | -34.3% | -88.0% | |
| – | – | – | – | – | |
| – | +360.5% | +41.0% | +46.5% | +50.1% | |
| – | +359.8% | +39.0% | +48.6% | +50.2% | |
| – | – | +9.4% | +15.7% | -91.4% | |
| – | +956.0% | +46.5% | -16.5% | +56.9% | |
| – | +323.2% | -13.3% | +70.3% | +19.2% | |
| – | – | – | – | – | |
| – | +2,524.4% | -4.6% | -1.5% | +22.2% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.